American Society of Hirudotherapy

Cell-free synthesis of the hirudin variant 1 of the blood-sucking leech Hirudo medicinalis

Research article published in Scientific reports (2020)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Drug DevelopmentGenomics & ProteomicsClinical TrialsWüstenhagen D et al. · Scientific reports, 2020

Summary

Synthesis and purification of peptide drugs for medical applications is a challenging task. The leech-derived factor hirudin is in clinical use as an alternative to heparin in anticoagulatory therapies.

Why This Matters for Hirudotherapy

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citation

Cell-free synthesis of the hirudin variant 1 of the blood-sucking leech Hirudo medicinalis.

Wüstenhagen D et al. · Scientific reports, 2020

DOI

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.